FEDERAL COURT OF AUSTRALIA
Albany Molecular Research Inc v Arrow Pharmaceuticals Pty Ltd (No 2)
[2011] FCA 426
Citation: Albany Molecular Research Inc v Arrow Pharmaceuticals Pty Ltd (No 2) [2011] FCA 426 Parties: ALBANY MOLECULAR RESEARCH, INC v ARROW PHARMACEUTICALS PTY LTD (ACN 003 144 170), SIGMA PHARMACEUTICALS PTY LTD LIMITED (ACN 088 417 403), SIGMA PHARMACEUTICALS (AUSTRALIA) PTY LTD (ACN 004 118 594) and SIGMA COMPANY LIMITED (ACN 004 132 923); AVENTIS PHARMACEUTICALS, INC File number: VID 883 of 2007 Judge: JESSUP J Date of judgment: 4 May 2011 Legislation: Federal Court Rules O 23 Cases cited: Albany Molecular Research Inc v Alphapharm Pty Ltd [2011] FCA 120
Albany Molecular Research Inc v Alphapharm Pty Ltd (No 2) [2011] FCA 425
Albany Molecular Research Inc v Arrow Pharmaceuticals Pty Ltd [2011] FCA 252
Calderbank v Calderbank [1976] Fam 93
CGU Insurance Ltd v Correction Corporation of Australia Staff Superannuation Pty Ltd [2008] FCAFC 173
Port of Melbourne Authority v Anshun Pty Ltd (1981) 147 CLR 589Date of hearing: Heard on the papers Date of last submissions: 13 April 2011 Place: Melbourne Division: GENERAL DIVISION Category: No Catchwords Number of paragraphs: 11 Counsel for the Applicant: Mr A Archibald QC with Mr A Ryan SC and Ms K Beattie Solicitor for the Applicant: Phillips Ormonde Fitzpatrick Counsel for the Respondents: Mr D Shavin QC with Ms H Rofe Solicitor for the Respondents: Corrs Chambers Westgarth
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
GENERAL DIVISION
VID 883 of 2007
BETWEEN: ALBANY MOLECULAR RESEARCH, INC
Applicant/First Cross-RespondentAVENTIS PHARMACEUTICALS, INC
Second Cross-RespondentAND: ARROW PHARMACEUTICALS PTY LTD (ACN 003 144 170)
First Respondent/First Cross-ClaimantSIGMA PHARMACEUTICALS PTY LTD LIMITED (ACN 088 417 403)
Third Respondent/Third Cross-ClaimantSIGMA PHARMACEUTICALS (AUSTRALIA) PTY LTD (ACN 004 118 594)
Fourth Respondent/Fourth Cross-ClaimantSIGMA COMPANY LIMITED (ACN 004 132 923)
Fifth Respondent/Fifth Cross-ClaimantJUDGE:
JESSUP J
DATE OF ORDER:
4 MAY 2011
WHERE MADE:
MELBOURNE
THE COURT ORDERS THAT:
1.Subject to Order 3 below, the applicant pay the respondents’ costs of the application.
2.Subject to Order 3 below, save for costs incurred only in connection with the allegations that the invention did not involve an inventive step, that the claims did not define the invention, that the claims were not clear and succinct, that the priority date was later than 24 June 1993, that the invention was not a manner of manufacture, that the complete specification did not describe the invention fully and that the claims were not fairly based on the matter described in the specification, the cross-respondents pay the cross-claimants’ costs of the cross-claim.
3.There be no order as to the costs incurred by the parties after 18 February 2011 in connection with their submissions as to the orders proper to be made to give effect to the court’s reasons of that date or as to costs, or in connection with the appearances associated with those submissions, those orders or costs.
Note:Settlement and entry of orders is dealt with in Order…
Keep reading for free
Create a free CaseChat account to read Albany Molecular Research Inc v Arrow Pharmaceuticals Pty Lt... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2011] FCA 426
- Decision Date
CaseChat Overview and Summary
The primary legal issues before the court were the validity of Albany's patent, the interpretation of the patent claims, and the extent of any infringement by Arrow. The court also needed to determine the appropriate costs orders in light of the extensive history of litigation between the parties. The court was tasked with deciding whether the patent was valid, the meaning of specific claim terms, whether Arrow's products fell within the scope of the patent claims, and how to allocate the costs between the parties given the nature and history of the litigation.
The court found that Albany's patent was valid and that Arrow had indeed infringed the patent. In reaching this decision, the court examined the claims of the patent in detail, the specifications, and prior art. The court determined that the claims were clear and that Arrow's products met the criteria of the patent. Regarding the costs, the court held that Albany should pay its own costs for the application, while Arrow was to bear the costs of the cross-claim, except for those related to specific allegations that were dismissed. The court made no order on costs incurred after a certain date to avoid further protracted litigation over costs.
The final orders reflected the court's determinations on the validity of the patent, the infringement by Arrow, and the costs to be borne by each party. Albany Molecular Research Inc was required to pay its own costs of the application, while Arrow Pharmaceuticals Pty Ltd was to pay the costs of the cross-claim, excluding certain specified costs. No order was made regarding costs incurred after a particular date, thereby concluding the financial aspect of the litigation.
Orders
Orders of the court
1. Subject to Order 3 below, the applicant pay the respondents’ costs of the application.
2. Subject to Order 3 below, save for costs incurred only in connection with the allegations that the invention did not involve an inventive step, that the claims did not define the invention, that the claims were not clear and succinct, that the priority date was later than 24 June 1993, that the invention was not a manner of manufacture, that the complete specification did not describe the invention fully and that the claims were not fairly based on the matter described in the specification, the cross-respondents pay the cross-claimants’ costs of the cross-claim.
3. There be no order as to the costs incurred by the parties after 18 February 2011 in connection with their submissions as to the orders proper to be made to give effect to the court’s reasons of that date or as to costs, or in connection with the appearances associated with those submissions, those orders or costs.
Note:
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi